Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
NCT00458796 · University of Leeds · NA · terminated · last registry update 2022-05-27 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lower than expected recruitment” | – | Registry record, University of Leeds |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FDPS in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-25Results posted on the registry: M.D. Anderson Cancer Center, Dasatinib + Zoledronic Acid (NCT00566618)
- 2021-12-21Phase 3 first posted: Assiut University, Zoledronic Acid 4 MG (NCT05164952)
- 2021-06-22Also stopped (terminated): First Affiliated Hospital, Sun Yat-Sen University, Zoledronate (NCT01623908)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision